Dennis Kim, MD, PhD

My research is aiming to develop projects of: 1) biomarker discovery using genomics in leukemias and allogeneic stem cell transplantation; and 2) clinical research in chronic myeloid leukemia and graft-versus-host disease after allogeneic stem cell transplantation.

I have also been involved in multiple exome sequencing projects in acute myleoid leukemia (AML) with normal karyotype and secondary AML progressed from antecedent hematologic malignancies, as well as chronic myeloid leukemia (CML). My future direction of genomic research is to integrate multi-omics platforms to investigate leukemia genomes, thus dissecting clonal structures in a refined way.

Not only in translational research, but also in the clinical research field, I have shown significant progress in three ways: 1) clinical database registry; 2) retrospective studies using the database; and 3) generation of prospective clinical trials in CML and in graft-versus-host disease (GVHD) and other post-transplant complications after allogeneic stem cell transplantation.  First of all, I developed a clinical database of allogeneic transplant patients (especially for GVHD and post-transplant complications) and CML patients (especially for treatment outcomes after tyrosine kinase inhibitor therapy). Secondly, I have participated in multiple ongoing clinical retrospective studies generated from the registry database. Thirdly, I am involved in  multiple clinical trials. Currently, I am the principal investigator of a pivotal Canadian tyrosine kinase inhibitor (TKI) discontinuation clinical trial and am also a chair of the correlative part of this trial, entitled "Treatment-free Remission Accomplished with Dasatinib (TRAD)". This is the first Canadian TKI discontinutation trial for the management of CML.
J Oncol Pharm Pract. 2020 Mar 17;:1078155220908948
Bacopoulos AJ, Ho L, Yang A, Ng P, Dara C, Loach D, Deotare U, Michelis FV, Viswabandya A, Kim DD, Lipton JH, Messner HA, Thyagu S
Eur J Haematol. 2020 Mar 01;:
Vasudevan Nampoothiri R, Law AD, Lam W, Chen C, Al-Shaibani Z, Loach D, Michelis FV, Kim DDH, Mattsson J, Kumar R, Lipton JH, Viswabandya A
Bone Marrow Transplant. 2020 Feb 05;:
Salas MQ, Prem S, Atenafu EG, Datt Law A, Lam W, Al-Shaibani Z, Loach D, Kim DDH, Michelis FV, Lipton JH, Kumar R, Mattsson J, Viswabandya A
BMJ. 2020 01 28;368:m141
Isaranuwatchai W, Teerawattananon Y, Archer RA, Luz A, Sharma M, Rattanavipapong W, Anothaisintawee T, Bacon RL, Bhatia T, Bump J, Chalkidou K, Elshaug AG, Kim DD, Reddiar SK, Nakamura R, Neumann PJ, Shichijo A, Smith PC, Culyer AJ
Haematologica. 2019 Dec;104(12):2327-2329
Bone Marrow Transplant. 2019 Nov 19;:
Mayo SJ, Messner HA, Rourke SB, Howell D, Victor JC, Lipton JH, Kuruvilla J, Gutpa V, Kim DDH, Michelis FV, Metcalfe K
Eur J Haematol. 2019 Nov 18;:
Prem S, Atenafu EG, Lam W, Law A, Michelis FV, Kim DDH, Viswabandya A, Howard Lipton J, Mattsson J, Kumar R
Bone Marrow Transplant. 2019 Oct 14;:
Alblooshi RM, Deotare U, Michelis FV, Thyagu S, Kim DDH, Lipton JH, ElGohary GM, Viswabandya A
Eur J Haematol. 2019 Sep 23;:
Salas MQ, Atenafu EG, Bautista MR, Prem S, Lam W, Datt Law A, Shaibani ZA, Kim DDH, Michelis FV, Lipton JH, Viswabandya A, Mattsson J, Kumar R
Eur J Haematol. 2019 Sep 12;:
Salas MQ, Lam W, Law AD, Kim DDH, Michelis FV, Loach D, Al-Shaibani Z, Lipton JH, Kumar R, Mattsson J, Viswabandya A